Abstract

ORDONEZ-BOSCHETTI, Laura et al. Clinical considerations on the introduction of ocrelizumab in Mexico. Rev. mex. neurocienc. [online]. 2020, vol.21, n.3, pp.97-103.  Epub Oct 25, 2021. ISSN 2604-6180.  https://doi.org/10.24875/rmn.20000153.

Multiple sclerosis (MS) is the leading cause of neurological disability among young adults. The disease-modifying treatments (DMTs) have been a breakthrough in the care of this patients, becoming a treatable disease. Today, we face a broad spectrum of treatment possibilities, which should be used rationally to provide the maximum benefit for the patients. In the context of the introduction of ocrelizumab as a treatment option in the Mexican MS DMT portfolio, a group of neurologists was convened to analyze the potential transition among DMT from their experience, through a desk research and expert opinion. As a result, here we describe the different considerations suggested for switching from different DMT to ocrelizumab that includes profiling studies, washout periods, and follow-up considerations. We concluded that the switch from other DMT previously used to ocrelizumab could be convenient and safe, as long as there is an adequate selection and profiling of the patients.

Keywords : Drug switching; Expert opinion; Mexico; Multiple sclerosis; Ocrelizumab; Disease-modifying treatment.